We are testing a new T-cell redirecting antibody for patients with CALR-mutated myeloproliferative neoplasms. This study aims to evaluate its safety and potential effectiveness in treating this condition.
Health conditions and diseases that the clinical trial is designed to study and treat.
CALR-mutated Myeloproliferative Neoplasms are a group of blood cancers that occur when the bone marrow produces too many blood cells due to mutations in the CALR gene, leading to symptoms like fatigue, weakness, and an increased risk of blood clots.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
